Genmab — September 2017
-
I am not sure if we posted this here last week, Tecentriq study to be placed on partial clinical hold, NCT02431208 is a Dara combo https://myelomaresearchnews.com/2017/09/20/safety-concerns-lead-to-partial-hold-on-2-tecentriq-trials-in-myeloma-and-lymphoma/
-
-
Ved ikke om dette nye studie er nævnt: https://clinicaltrials.gov/ct2/show/NCT03289299?term=NCT03289299&rank=1
-
God morgen.
-
Check lige hvor meget danske banker har købt for... Køberne er generelt helt væk
-
Mon ikke en masse investorer er på vej væk fra GEN efter 1.linie read out? Nu er risikoen og upside ifm risiko væk, og vi kigger mere på omsætningstal. Det er nok en anden investorgruppe, vi skal have fat i
-
GEN er stadig early days for P/E investorerne
-
Hvis Bava havde præsenteret tisotumab data var kursen nok fordoblet, mens det ingen effekt har på GEN pga dara's værdi.
-
Til gengæld ligger GEN lige i sweetspot for et opkøb. Hvis det altså skulle komme...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind